A Phase II Study of F182112 Combined With Different Administration Regimens in Patients With Relapsed or Refractory Multiple Myeloma
This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.
• Be diagnosed with multiple myeloma according to the IMWG 2016 criteria.
• The previous treatment regimen must contain lenalidomide (lenalidomide must be used continuously for at least 2 cycles) and a proteasome inhibitor.
• Participants whose previous treatment regimen contained pomalidomide or who were intolerant to pomalidomide cannot be enrolled.
• Have an ECOG performance status score of 0 - 2.
• Meet at least one of the following measurable disease indicators:
‣ Serum M - protein ≥ 5 g/L.
⁃ Urine M - protein ≥ 200 mg/24 h.
⁃ Serum free light chain (FLC) test: Involved FLC level ≥ 100 mg/L and abnormal serum free light chain ratio (\< 0.26 or \> 1.65).